In the current study, we showed that G2/M blockers such as barasertib (AZD1152, AukB inhibitor) or volasertib (BI 6727, a PLK1 inhibitor) are promising anti-cancer approaches in resistant cells. The gene discussed is PLK1; the disease is cancer.